Matthew Wikler
Director/Board Member bei MATINAS BIOPHARMA HOLDINGS, INC.
Vermögen: 78 718 $ am 31.03.2024
Profil
Matthew A.
Wikler currently works at Matinas BioPharma Holdings, Inc., as Independent Director from 2018 and IDTD Consulting SASU, as Principal.
Dr. Wikler also formerly worked at Shire ViroPharma, Inc., as President & Chief Executive Officer, Ortho-McNeil Pharmaceutical LLC, as President & Chief Executive Officer, Clinical & Laboratory Standards Institute, Inc. (Pennsylvania), as Vice Chairman, Bristol Myers Squibb Co., as Senior Medical Director-Infectious Diseases from 1997 to 2001, US Food & Drug Administration, as Deputy Director-Anti-infective Drug Products from 1994 to 1995, The Medicines Co., as Vice President-New Business Ventures from 2012 to 2015, Peninsula Pharmaceuticals, Inc., as Chief Medical Officer & Executive Vice President in 2005, IASO Pharma, Inc., as President, Chief Executive & Financial Officer, Melinta Subsidiary Corp., as Chief Development Officer, MPEX Pharmaceuticals, Inc., as Chief Medical Officer in 2006, and PATH Drug Solutions, as Chief Medical Officer in 2010.
Dr. Wikler received his undergraduate degree from Franklin & Marshall College, Masters Business Admin degree from The Wharton School of the University of Pennsylvania, and doctorate degree from Temple University School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 18.03.2024 | 290 472 ( 0,13% ) | 78 718 $ | 31.03.2024 |
Aktive Positionen von Matthew Wikler
| Unternehmen | Position | Beginn |
|---|---|---|
| MATINAS BIOPHARMA HOLDINGS, INC. | Director/Board Member | 01.01.2018 |
| IDTD Consulting SASU | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Matthew Wikler
| Unternehmen | Position | Ende |
|---|---|---|
| THE MEDICINES COMPANY | Corporate Officer/Principal | 01.01.2015 |
| PATH Drug Solutions | Chief Tech/Sci/R&D Officer | 26.02.2010 |
MPEX Pharmaceuticals, Inc.
 MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services MPEX Pharmaceuticals, Inc. develops and manufactures therapies for antibiotic resistance with focus on gram-negative organisms. It offers Aeroquin (MP- 376), an aerosol formulation of levofloxacin for the treatment of pulmonary infections in patients with cystic fibrosis, as well as antibiotic programs to address antibiotic resistance in gram negative organisms. The company was founded in 2001 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | 01.11.2006 |
Peninsula Pharmaceuticals, Inc.
 Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA. | Chief Tech/Sci/R&D Officer | 01.12.2005 |
| BRISTOL-MYERS SQUIBB COMPANY | Chief Tech/Sci/R&D Officer | 01.01.2001 |
Ausbildung von Matthew Wikler
| Franklin & Marshall College | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| Temple University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| MATINAS BIOPHARMA HOLDINGS, INC. | Health Technology |
| Private Unternehmen | 11 |
|---|---|
Shire ViroPharma, Inc.
 Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Health Technology |
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
Peninsula Pharmaceuticals, Inc.
Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA. | Commercial Services |
IASO Pharma, Inc.
 IASO Pharma, Inc. Pharmaceuticals: MajorHealth Technology IASO Pharma, Inc. operated as a development stage biopharmaceutical company which focused on acquiring, developing and commercializing drugs for the treatment and prevention of infectious diseases and other serious illnesses. The company was founded on October 5, 2006 and is headquartered in San Diego, CA. | Health Technology |
Ortho-McNeil Pharmaceutical LLC
 Ortho-McNeil Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Ortho-McNeil Pharmaceutical LLC manufactures pharmaceutical products. Its products include ditropan, elmiron, modicon, otho cept and ortho novum etc. The company was founded in 1993 and is headquartered in Raritan, NJ. | Health Technology |
Melinta Subsidiary Corp.
 Melinta Subsidiary Corp. Pharmaceuticals: MajorHealth Technology Melinta Subsidiary Corp. develops and markets pharmaceutical products for the treatment of life-threatening infections. It also develops novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens. The company was founded by John N. Abelson, Harry F. Noller, Susan Froshauer, Harry H. Penner, Jr., William L. Jorgensen, Thomas A. Steitz, and Peter Moore in October 2000 and is headquartered in New Haven, CT. | Health Technology |
US Food & Drug Administration
 US Food & Drug Administration General GovernmentGovernment US Food & Drug Administration operates agencies to protect health and human services. It protects and promotes public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices, cosmetics, animal foods and feed and veterinary products. The company was founded by Theodore Roosevelt and Harvey Washington Wiley on 30th June, 1906 and is headquartered in Silver Spring, MD. | Government |
MPEX Pharmaceuticals, Inc.
MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services MPEX Pharmaceuticals, Inc. develops and manufactures therapies for antibiotic resistance with focus on gram-negative organisms. It offers Aeroquin (MP- 376), an aerosol formulation of levofloxacin for the treatment of pulmonary infections in patients with cystic fibrosis, as well as antibiotic programs to address antibiotic resistance in gram negative organisms. The company was founded in 2001 and is headquartered in San Diego, CA. | Commercial Services |
Clinical & Laboratory Standards Institute, Inc. (Pennsylvania)
 Clinical & Laboratory Standards Institute, Inc. (Pennsylvania) Miscellaneous Commercial ServicesCommercial Services Clinical & Laboratory Standards Institute is a non profit organization which develops clinical and laboratory practices and promoting their use worldwide. it offers education, membership, and specialty areas which include general laboratory, newborn screening, clinical chemistry and toxicology, hematology, and quality management systems. The company was founded in 1968 and is headquartered in Wayne, PA. | Commercial Services |
| PATH Drug Solutions | Commercial Services |
| IDTD Consulting SASU |
